Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxymetazoline for bleeding reduction during septorhinoplasty
IRCT20230514058190N1Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of oxymetazoline in epistaxis (2 arms), sponsored by Islamic Azad University. Primary endpoints: Bleeding rate, Surgeon satisfaction with surgical field and 10 more. Started Jul 2023; status: completed.
02
Drugs
oxymetazoline
03
Conditions
epistaxis
Beyond the preview
Go deeper on IRCT20230514058190N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230514058190N1.